Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 6, pp 1015–1026 | Cite as

Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae

Original Article

Abstract

Purpose

Fructus Schizandrae (FS) is commonly used as a tonic in traditional Chinese medicine. Recently, FS was found to significantly improve liver dysfunction in chronic hepatitis patients. The present study was to assess the reversal effect of five schizandrins and crude extract from FS (named LCC) on multidrug resistance (MDR) of cancer cells, both in vitro and in vivo. Chemically, the five schizandins are derivatives of dibenzo-(a, c)-cyclooctene lignan with distinct structures differing from any known MDR reversal agents.

Methods

A panel of sensitive and resistant cancer cell lines were treated with various concentrations of LCC and schizandrins. Drug sensitivity, accumulation of Doxorubicin (Dox), expression of P-glycoprotein and protein kinase C (PKC), and apoptosis were determined in vitro. The in vivo effect was tested in nude mice grafted with sensitive and resistant human epidermal cancer cell line to vincristine (VCR) (KB, KBv200).

Results

The tested five compounds at 25 μM showed various levels of MDR reversal activity, of which, schizandrin A (Sin A) was the most potent one. Sin A reversed VCR resistance in KBv200 cells, MCF-7/Dox cells and Bel7402 cells by 309-, 38-, and 84-folds, respectively. Also, Sin A reversed the resistance of Dox in the above cancer cell lines. LCC at 25 μg/ml reversed VCR resistance by 619-folds in KBv200, 181-folds in MCF-7/Dox cell line, and 1,563-folds in innate resistance of human hepatic cellular carcinoma Bel7402 cells to VCR. Furthermore, LCC and its active component Sin A potently reversed the cross-resistance to paclitaxel in those cell lines. Both Sin A and LCC markedly increased intracellular Dox accumulation and enhanced apoptosis, down-regulated Pgp protein and mRNA and total PKC expression in MDR cells. Coadministration of LCC (p.o.) significantly potentiated the inhibitory effect of VCR (i.p.) on tumor growth in nude mice bearing KBv200 xenograft.

Conclusions

The LCC and its active component Sin A have remarkable reversal effect on MDR in cancer cells by inhibition of both the function and expression of Pgp and total PKC.

Keywords

Multidrug resistance Pgp Fructus Schizandrae Schizandrins 

Abbreviations

FS

Fructus Schizandrae

Sin A

Schizandrin A

Sin B

Schizandrin B

Sin C

Schizandrin C

Sol A

Schizandrol A

Sol B

Schizandrol B

VPL

Verapamil

Dox

Doxorubicin

MDR

Multidrug-resistance

Pgp

P-glycoprotein

LCC

Crude extract of Fructus Schizandrae

PKC

Protein kinase C

VCR

Vincristine

MTT

3-(4,5-Dimethylthiazole-2-yle)-2,5-diphenyltetrazolium bromide

Rho 123

Rhodamine 123

PI

Propidium iodide

FITC

Fluorescence isothiocyanate

LPS

Lipopolysaccharides

CAM

Camptothecin

ETO

Etoposide

NBT

Nitroblue tetrazolium chloride

BCIP

5-Bromo-4-chloro-3-inDoxyl-phosphate

Notes

Acknowledgment

This work was supported by the Natural Science Foundation of China (No. 30630069).

References

  1. 1.
    Klopman G, Shi LM, Ramu A (1997) Quantitative structure-activity relationship of multidrug resistance reversal agents. Mol Pharmacol 52:323–334PubMedGoogle Scholar
  2. 2.
    Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedCrossRefGoogle Scholar
  3. 3.
    Breier A, Barancik M, Sulova Z, Uhrik B (2005) P-glycoprotein–implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5:457–468PubMedCrossRefGoogle Scholar
  4. 4.
    Gottesman MM (2002) Mechanism of cancer drugs resistance. Annu Rev Med 53:615–627PubMedCrossRefGoogle Scholar
  5. 5.
    Takara K, Sakaeda T, Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12:273–286PubMedCrossRefGoogle Scholar
  6. 6.
    Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18:2905–2917PubMedGoogle Scholar
  7. 7.
    Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T (2002) Reversal of multidrug resistance: lessons from clinical oncology. Novartis Found Symp 243:83–96; discussion 96–102, 180–5PubMedCrossRefGoogle Scholar
  8. 8.
    Ojima I, Geney R, Ungureanu IM, Li D (2002) Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life 53:269–74PubMedCrossRefGoogle Scholar
  9. 9.
    Peer D, Margalit R (2006) Fluoxetine and reversal of multidrug resistance. Cancer Lett 237:180-187PubMedCrossRefGoogle Scholar
  10. 10.
    O’Brian CA, Ward NE, Stewart JR, Chu F (2001) Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer—an evolving story. Cancer Metastasis Rev 20:95–100PubMedCrossRefGoogle Scholar
  11. 11.
    Hardy SP, Valverde MA, Goodfellow HR, Higgins CF, Sepulveda FV (1994) Regulation of volume activated chloride channels by protein kinase C-mediated phosphorylation of P-glycoprotein. Jpn J Physiol 44(Suppl 2):S9–S15PubMedGoogle Scholar
  12. 12.
    Lelong-Rebel IH, Cardarelli CO, Hardy SP, Valverde MA, Goodfellow HR, Higgins CF, Sepulveda FV (2005) Differential phosphorylation patterns of P-glycoprotein reconstituted into a proteoliposome system: insight into additional unconventional phosphorylation sites. Anticancer Res 25:3925–3935PubMedGoogle Scholar
  13. 13.
    Masanek U, Stammler G, Volm M (2002) Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2:37–41PubMedCrossRefGoogle Scholar
  14. 14.
    Beck JF, Brugger D, Brischwein K, Liu C, Bader P, Niethammer D, Gekeler V (2001) Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblast cell line CCRF-CEM and in blasts from patients with acute lymphoblast leukemias. Jpn J Cancer Res 92:896–903PubMedGoogle Scholar
  15. 15.
    Brugger D, Brischwein K, Liu C, Bader P, Niethammer D, Gekeler V, Beck JF (2002) Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res 22:4229–4232PubMedGoogle Scholar
  16. 16.
    Liu GT (1989) Pharmacological actions and clinical use of Fructus Schizandrae. Chin Med J (Engl) 102:740–749Google Scholar
  17. 17.
    Liu GT, Wang GF, Wei HL, Bao TT, Song ZY (1979) A comparison of the protective actions of biphenyl dimethyl-dicarboxylate, transtilbene, alcoholic extracts of Fructus Schizandrae and ganoderma against experimental liver injury in mice. Acta Pharmacol Sin 1:598–604Google Scholar
  18. 18.
    Liu KT, Cresteil T, Columelli S, Lesca P (1982) Pharmacological properties of dibenzo [a, c] cyclooctene derivatives isolated from Fructus Schizandraee chinensis. II. Induction of phenobarbital-like hepatic monooxygenases. Chem Biol Interact 39:315–330PubMedCrossRefGoogle Scholar
  19. 19.
    Lu H, Liu GT (1991) Antioxidant activity of dibenzocyclooctene lignans isolated from Schizandraecea. Planta Med 58:311–315CrossRefGoogle Scholar
  20. 20.
    Liu KT, Lesca P (1982) Pharmacological properties of dibenzo [a, c] cyclooctene derivatives isolated from Fructus Schizandrae chinensis. I. Interaction with rat liver cytochrome P-450 and inhibition of xenobiotics metabolism and mutagenicity. Chem Biol Interact 39:301–314PubMedCrossRefGoogle Scholar
  21. 21.
    Huang M, Liu GT (1999) The study of innate drug resistance of human hepatocellular carcinoma Bel7402cll line. Cancer Lett 135:97–105PubMedCrossRefGoogle Scholar
  22. 22.
    Chen YY, Shu ZB, Li NL (1976) Studies on Fructus Schisandrae. IV. Isolation and determination of the active components (in lowering high serum ALT levels) of Fructus Schisandrae Sinensis Baill. Sci Sin XIX(1):278–280Google Scholar
  23. 23.
    Chen YY, Yang YC (1982) Studies on the serum ALT-lowering active component of the Fructus Schisandrae Rubriflora Rhed et Wils. Acta Pharmacol Sin 17:312–315Google Scholar
  24. 24.
    Fu LW, Zhang YM, Liang YJ, Yang XP, Pan QC (2002) The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenograft derived from human breast adenocarcinoma MCF-7/Dox cells. Eur J Cancer 38:418–426PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang XH, Zhang FY, Ji XJ, Li ZY (1994) [Vincristine-resistant human KB cell line and mechanism of multidrug resistance]. Yao Xue Xue Bao 29:246–51PubMedGoogle Scholar
  26. 26.
    Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semi-automated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–942PubMedGoogle Scholar
  27. 27.
    Fang M, Zhang HQ, Xue SB, Pang DB, Chi XS (1994) Apoptosis resistance and its reversal in harringtonine resistant cell line. Yao Xue Xue Bao 29:891–898PubMedGoogle Scholar
  28. 28.
    Telford WG, King LE, Fraker PJ (1994) Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods 172:1–16PubMedCrossRefGoogle Scholar
  29. 29.
    Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN (1990) Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–1756PubMedGoogle Scholar
  30. 30.
    Bonsing BA, Corver WE, Gorsira MC, van Vliet M, Oud PS, Cornelisse CJ, Fleuren GJ (1997) Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry 28:11–24PubMedCrossRefGoogle Scholar
  31. 31.
    Lowry OH, Rosenbrough NJ, Farr AL (1951) Protein measurement with the folin phenol reagent. J biol Chem 193:265–275PubMedGoogle Scholar
  32. 32.
    Jin J, Wang FP, Wei H, Liu G (2005) Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol 55:179–188PubMedCrossRefGoogle Scholar
  33. 33.
    Laginha KM, Verwoert S, Charrois GJ, Allen TM (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11(19pt):6944–6949PubMedCrossRefGoogle Scholar
  34. 34.
    Greenlund LJ, Deckwerth TL, Johnson EM Jr (1995) Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 14:303–315PubMedCrossRefGoogle Scholar
  35. 35.
    Loe DW, Oleschuk CJ, Deeley RG, Cole SP (2000) Structure-activity studies of verapamil analogs that modulate transport of leukotriene C(4) and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 275:795–803PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Pharmacology, Institute of Materia MedicaPeking Union Medical College and Chinese Academy of Medical SciencesBeijingChina
  2. 2.Division of Oncology, Department of Internal MedicineStanford UniversityStanfordUSA
  3. 3.Welsh School of PharmacyCardiff University CardiffUK

Personalised recommendations